ENLIVEX

As a clinical:stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, Sepsis and other indications. Our pioneering Allocetra™ cell:based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.